



## **Cristina Bottino**

Full professor

✉ cristina.bottino@unige.it

☎ +39 010 3537 886

☎ +39 010 56362 845

### ***Education and training***

**1985**

#### **Medical Doctor (M.D.) degree**

110/110 cum laude

School of Medicine University of Genova - Genova - IT

**2015**

#### **Healthcare Management Degree**

Development of a diagnostic-therapeutic-care way for the identification of T and NK cytotoxic related primary immunodeficiencies

Accademia Management Sanitario (AMAS) University of Genova - Genova - IT

### ***Academic experience***

**2006 - ONGOING**

#### **Full Professor**

Dip. Exp.Medicine School of Medicine University of Genova - Genova - IT

### ***Work experience***

**1986 - 1988**

#### **Postdoctoral Fellow Laboratory of Human Immunology**

Ludwig Institute for Cancer research - Lausanne - CH

**1989 - 2001**

#### **Staff Member Laboratory of Immunology**

Istituto Nazionale per la Ricerca sul Cancro (IST) - Genova - IT

**2001 - 2006**

#### **Staff Member Laboratory of Clinical and Experimental Immunology**

IRCCS Istituto G. Gaslini - Genova - IT

Head Molecular Immunology Unit

**2006 - ONGOING**

#### **Head of the Laboratory of Clinical and Experimental Immunology**

IRCCS Istituto G. Gaslini - Genova - IT

## ***Language skills***

### **Italian**

Mother tongue

### **English**

Independent

### **French**

Independent

## ***Teaching activity***

Physiopathology, Medical School

Pathology, Dental School

Pathology and Physiopathology, Physiotherapy school

## ***Postgraduate research and teaching activity***

### **Supervision of PhD students, residents and post-doctoral fellows**

Supervisor of doctoral students (Clinical and Experimental Immunology doctoral school, University of Genova), specialization students (Clinical Pathology specialization school, University of Genova) and fellowships

### **PhD committees membership**

Member of the 'Clinical and Experimental Immunology' doctoral school, University of Genova

### **Postgraduate (PhD) teaching activity**

Professor of the 'Clinical and experimental Immunology' doctoral school and Clinical Pathology specialization school, University of Genova

## ***Research interests***

The Cristina Bottino's research activity is focused on the analysis of the molecular mechanisms regulating the immune mediated recognition of tumors and virus-infected cells in human. Since 1990 a major object of her research has been the study of the function of Natural Killer cells (NK) in physiological and pathological conditions such as tumors and primary immunodeficiencies (PID).

1) Discovery and molecular characterization of the HLA-class I-specific inhibitory receptors (iKIR, CD94/NKG2A) and their activating counterparts (aKIR, CD94/NKG2C); 2) identification of the (non-MHC specific) activating NK receptors and co-receptors NKp46, NKp30, NKp44, 2B4, NKp80 and NTB-A; 3) Identification of PVR and Nectin-2, ligands of DNAM-1 activating receptor; 4) demonstration that of NTB-A displays homophilic recognition; 5) Characterization of the NK cell function patients with XLP1, LAD1 and FHL immunodeficiencies ; 6) analysis of the molecular interactions involved in NK/DC and NK/macrophage crosstalk in physiological conditions and in the tumor microenvironment; 7) demonstration that NK cells are able to kill tumor cells with stem cell properties (CSC) as well as the tumor-associated endothelium.

Since 2003 she focused her research on high-risk Neuroblastoma (NB). She characterized the receptor/ligand interactions involved in the NK cells-mediated recognition of NB and identified different tumor escape mechanisms. In particular, she identified B7-H3, a novel immune checkpoint ligand protecting NB from NK-mediated recognition. Moreover, she demonstrated that: i) in a percentage of NB patients tumor cells downregulate the expression of PVR escaping NK cell-mediated killing; ii) NB cells release TGF- $\beta$ 1 that modulates in NK cells the repertoire of activating and chemokine receptors ; iii) NB cells express/upregulate the immune checkpoint ligand PD-L1 that interacting with the PD-1 limits immune surveillance ; iv) NB patients may benefits from treatment with Tyrosine kinase inhibitors (TKIs) such as Imatinib mesylate that exert off-Target effects on NK, Monocytes, and M2 Macrophages

### ***Other professional activities***

Head of the Laboratory of Clinical and Experimental Immunology, IRCCS Istituto G. Gaslini, Genova, Italy  
Member of REPRISE (MIUR), Basic Research  
Scientific Advisory Board Member of the the biotech start-up React4life (<https://www.react4life.com>)